Markets Rise Ahead ...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$47.86 0.26 | 0.55%
02/08/12 - 01:39 PM ET
640.85K / 1.43M
Vol / Avg. Vol:47.47 / 47.60
Open / Prev. Close:47.42 - 47.86
Today's Range:40.89 - 52.54
52 Wk Range:2.83%
Performance YTD:TheStreet Rating:
Portfolios with AZN
- Portfolio NameUser Type
- User2012 performers
- ContributorHighest-Yielding Drug Stocks
- Contributor6 European Stocks Resistant...
- UserMoney Maker
- Userkeithj
- ContributorRocket Stocks for the Week ...
- ProJohn Hussman
- ProEdward Owens
- UserKeith's dividend portfolio
- User201104
Latest AZN Headlines from TheStreet
- Layoffs Continue to Mount 02.08.12 | 11:02 am
- Stocks to Watch: Bank of America, Morgan Stanley, Kodak 01.19.12 | 05:01 am
- Theravance Shares Slide on Lung Drug Deaths 01.09.12 | 09:01 am
- Deutsche Telekom, Lockheed Martin: Hot Trends
12.20.11 | 10:12 am - Deutsche Telekom, Lockheed: Hot Trends 12.20.11 | 08:12 am
- AstraZeneca PLC (AZN): Today's Featured Drugs Loser 11.08.11 | 04:11 pm
- Targacept Trial Tragedy Takeaway: Don't Trust Clinical Data From India 11.08.11 | 12:11 pm
- Market Morning: Italy Fears Roil Markets 11.08.11 | 07:11 am
- Targacept Depression Drug Fails Late-Stage Study 11.08.11 | 06:11 am
- Pharma and Wall Street's Untapped Resource 10.25.11 | 06:10 am
Press Releases for AZN
- AstraZeneca US Broadens Income Eligibility For Prescription Savings Programs - Business Wire 02.08.12 | 09:02 am
- AstraZeneca Recognized As A Top Company For Female Executives - Business Wire 02.07.12 | 10:02 am
- AstraZeneca Fourth Quarter And Full-Year 2011 Results - Interviews - PR Newswire 02.02.12 | 05:02 am
- AstraZeneca, United Way Of Delaware Kick Off Statewide Youth Health Initiative - Business Wire 01.20.12 | 01:01 pm
- Bristol-Myers Squibb And AstraZeneca Receive Complete Response Letter From U.S. Food And Drug Administration For Dapagliflozin - Business Wire 01.19.12 | 02:01 am
- New Data Show Investigational Compound Dapagliflozin When Added To Glimepiride Maintained Reductions In Blood Sugar Levels In Adults With Type 2 Diabetes Over 48 Weeks Of Treatment - Business Wire 12.08.11 | 03:12 am
- AstraZeneca To Streamline US Sales Organization - Business Wire 12.07.11 | 01:12 pm
- Despite Trend Of Therapeutic Substitution, Survey Data Shows Patients Want Their Physician To Be The Ultimate Decision Maker On Their Rx Medications - Business Wire 12.05.11 | 09:12 am
- U-M Medical School And MedImmune Join Forces To Accelerate Search For New Therapies - PR Newswire 11.21.11 | 10:11 am
- Meta-Analysis Of Clinical Data On Cardiovascular Safety Presented For Investigational Compound Dapagliflozin In Adult Patients With Type 2 Diabetes - Business Wire 11.16.11 | 04:11 pm
Partner Headlines for AZN
- The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Pfizer and AstraZeneca - Press Releases - Zacks 02.07.12 | 09:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- An Income-Growth Portfolio For 2012: 4%+ Yield, Dividend Growth And Lower Beta - Seeking Alpha 02.02.12 | 08:02 am
- 8 High Dividend Stocks With Strong Fundamentals - Seeking Alpha 01.27.12 | 09:01 am
- FDA Rejection Of Dapaglifozin Means Little For Lexicon - Seeking Alpha 01.20.12 | 10:01 am
- Diabetes Drug Hits Dead End - Seeking Alpha 01.20.12 | 07:01 am
- 4 Dividend Stocks To Consider And 2 To Avoid - Seeking Alpha 01.17.12 | 07:01 am
- 10 Mega-Cap Stocks With Positive Receivable Trends - Seeking Alpha 01.12.12 | 09:01 am
- Dogs Of The NYSE International 100 Index 2011 Review - Seeking Alpha 01.09.12 | 09:01 am
- Benchmarking My Total Growth Dividend-Stock Portfolio - Seeking Alpha 01.05.12 | 08:01 am
